DRUG DISCOVERY OF PKB INHIBITORS AS ANTI-TUMOR AGENTS

PKB 抑制剂作为抗肿瘤药物的药物发现

• 批准号: 8360695
• 负责人: Joel Kenji Kawakami
• 金额: $ 7.46万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360695
• 关键词: Biological Factors; Education; Funding; Grant; Hawaii; Investigation; Laboratory Research; Lead; Molecular Models; National Center for Research Resources; Pharmaceutical Preparations; Principal Investigator; Proto-Oncogene Proteins c-akt; Research; Research Infrastructure; Resources; Screening procedure; Source; Structure; United States National Institutes of Health; Universities; antitumor agent; base; cancer therapy; computational chemistry; cost; drug discovery; inhibitor/antagonist; molecular modeling; novel; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Our research endeavor is the discovery and investigation of novel compounds as potential drugs for the treatment of cancer. The focus will center on the discovery of PKB (Protein Kinase B) inhibitors utilizing a structure based molecular modeling approach followed by lead optimization guided by computational chemistry. In another avenue, discovery of novel PKB inhibitors will be searched from a diverse source of natural product compounds isolated from research programs within our Department at Chaminade University as well as the screening of the same from various academic research laboratories in Hawaii.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其他NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 我们的研究奋进是发现和调查小说 化合物作为治疗癌症的潜在药物。 的 重点将集中在PKB（蛋白激酶B）的发现 利用基于结构的分子模拟方法的抑制剂 然后是由计算化学引导的先导物优化。 在另一个途径，新的PKB抑制剂的发现将是 从天然产物化合物的不同来源中搜索 与我们部门内的研究项目隔离， 查米纳德大学以及筛选相同的从 夏威夷的各种学术研究实验室。